Bharat Biotech reiterates its assurance on safety of Covaxin

As per company, the vaccine hasn't reported any incidents of blood clots, Thrombocytopenia, TTS, VITT, pericarditis, myocarditis, etc.

New Delhi: India’s leading vaccine manufacturer, Bharat Biotech has stated that the studies and safety follow-up activities demonstrated an excellent safety record for its Covid-19 vaccine, Covaxin.
As per the company, there have been no incidents of blood clots, Thrombocytopenia, TTS, VITT, pericarditis, and myocarditis.
The company’s statement issued on May 02, 2024 emphasized: “As seasoned innovators and product developers, the Bharat Biotech team was well aware that, while the efficacy of COVID-19 vaccines may be short-lived, the impact on patient safety could last a lifetime.”
The statement comes at a time when global pharmaceutical manufacturer, AstraZeneca has admitted that its Covid-19 vaccine, developed by researchers from the Oxford University, can cause a rare side effect of blood clotting and low platelet count after immunization.
“Covaxin was developed with a single-minded focus on safety first, followed by efficacy. It was the only COVID-19 vaccine in the Government of India’s COVID-19 immunization program to have conducted efficacy trials in India. It was evaluated in more than 27,000 subjects as part of its licensure process,” said the company.
“The vaccine was licensed under restricted use in clinical trial mode, where detailed safety reporting was carried out for several hundred thousand subjects. Safety of Covaxin was also evaluated by the Ministry of Health, Govt of India. Ongoing safety monitoring (pharmacovigilance) was continued throughout the product life cycle of the vaccine,” added the company’s statement.
It is worthwhile to note that a section of intellectuals and media in the middle of the pandemic had battled for the international vaccine manufacturers, raising doubts about the capabilities of indigenous research and manufacturing.